Medtronic is expected to release its fourth quarter and fiscal year 2018 financial results May 24, according to Zacks.
Similar to its first, second and third quarter financial results, Medtronic is expected to see growth in all of its business segments. The company attributes its constant growth to therapy innovation, globalization and the increase in its economic value.
Within Medtronic's cardiac and vascular group, the company is expected to maintain its market share while seeing growth from its new therapies. Medtronic's recent FDA approval of the Resolute Onyx 2.0 mm DES will boost this business segment.
Similarly, the minimally invasive therapies group is expected to register steady growth. The growth is due to new products Medtronic launched throughout the year.
Medtronic's restorative therapies group experienced a 5 percent increase for the full year of 2017, and it is expected the business segment will produce similar growth for the full year of 2018. Its recent introductions in the brain therapy space may push the segment to generate the most growth.